# JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

Study · id `cardio:ct-nct05064540` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05064540](<https://clinicaltrials.gov/study/NCT05064540>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05064540

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 450 participants.

## Technical summary

Registry record NCT05064540. Randomized; no masking; primary purpose treatment. Start 2021-09-20 (actual); primary completion 2032-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT05064540, source copy `cardio:ctgov-nct05064540-2026-09-09`, retrieved 2026-11-18)
- Started: 2021-09-20 (actual) (ClinicalTrials.gov record NCT05064540, source copy `cardio:ctgov-nct05064540-2026-09-09`, retrieved 2026-11-18)
- Primary completion: 2032-03 (anticipated) (ClinicalTrials.gov record NCT05064540, source copy `cardio:ctgov-nct05064540-2026-09-09`, retrieved 2026-11-18)
- Completion: 2032-03 (anticipated) (ClinicalTrials.gov record NCT05064540, source copy `cardio:ctgov-nct05064540-2026-09-09`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT05064540, source copy `cardio:ctgov-nct05064540-2026-09-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05064540-2026-09-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
- Acronym: JAGUAR
- Condition: AAA
- Condition: AAA - Abdominal Aortic Aneurysm
- Intervention (Device): Alto Abdominal Stent Graft System
- Intervention (Device): FDA Approved EVAR AAA Graft Systems
- Lead sponsor: Endologix
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Abdominal aortic aneurysm (`cardio:abdominal-aortic-aneurysm`)
- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: Endologix (`cardio:org-endologix`)

## Provenance

Content hash: 836c42c2f72761e357a2b911394f4350e1ec3908f4edeae6651c84be83c4b023
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
